We have located links that may give you full text access.
English Abstract
Journal Article
[Real-world efficacy of current lipid-lowering strategies in patients with acute coronary syndrome. Time to change the paradigm for treatment].
Giornale Italiano di Cardiologia 2023 January
Current guidelines on the management of dyslipidemias of the European Society of Cardiology/European Atherosclerosis Society recommend reducing low-density lipoprotein cholesterol (LDL-C) in patients after an acute coronary syndrome (ACS) by ≥50% compared to baseline values with a LDL-C level below 1.4 mmol/l (55 mg/dl) (class I recommendation, level of evidence A). However, in the real world, a low proportion of patients is treated according to the recommended lipid-lowering therapies and, as a consequence, very few people reach these targets. We analyzed seven recent studies reporting data on lipid control in 36 354 patients who were at very high risk because of a previous ACS in Europe. Overall, only 12.1% (95% confidence interval 9.8-13.5) of the patients achieved the recommended LDL-C levels, highlighting the gap between guidelines and current clinical practice. Indeed, the so-called stepwise strategy, although effective from a theoretical point of view, seems hardly applicable in the real world, underlying the need for new therapeutic strategies and algorithms. Based on these observations, a protocol has been proposed for the appropriate management of LDL-C levels in post-ACS patients both in terms of therapeutic choice and timing of treatment use.
Full text links
Related Resources
Trending Papers
The New Challenge of Obesity - Obesity-Associated Nephropathy.Diabetes, Metabolic Syndrome and Obesity 2024
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Oral Anticoagulation Use in Individuals With Atrial Fibrillation and Chronic Kidney Disease: A Review.Seminars in Nephrology 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app